Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Deferred revenue by Year
Deferred revenue — Collaboration arrangements (legacy disaggregation) ($M) ($M)
Moderna Deferred revenue: $6M in FY2024, down 82.4% from a year earlier. No newer figure appears in the documents we track.
Latest, FY2024
6
Period ended Dec 31, 2024
Change on a year earlier
-82.4%
34 in FY2023
History
6 years
Since FY2019
Sources
5
Documents cited below
Where the FY2024 figure comes from
Source: Form 10-K (filed 2025-02-21) ↗
Reported in Form 10-Q / 10-K Contract Liabilities.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Deferred revenue — Collaboration arrangements (legacy disaggregation) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 6 | -82.4% | Form 10-K (filed 2025-02-21) ↗ |
| FY2023 | Dec 31, 2023 | 34 | -58.0% | Form 10-K (filed 2025-02-21) ↗ |
| FY2022 | Dec 31, 2022 | 81 | -60.3% | Form 10-K (filed 2024-02-23) ↗ |
| FY2021 | Dec 31, 2021 | 204 | -15.0% | Form 10-K (filed 2023-02-24) ↗ |
| FY2020 | Dec 31, 2020 | 240 | +20.3% | Form 10-K (filed 2022-02-25) ↗ |
| FY2019 | Dec 31, 2019 | 200 | – | Form 10-K (filed 2021-02-26) ↗ |
Cite this data
StockData. (2026). Moderna Deferred revenue ($M), annual FY2019–FY2024 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/def-rev-collab-leg
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.